The SCD1 inhibitor aramchol interacts with regorafenib to kill GI tumor cells in vitro and in vivo (IMAGE)
Caption
Figure 11: Aramchol and regorafenib interact to suppress tumor growth in vivo. (A) Studies were performed per USDA regulations under approved VCU IACUC protocol AD20008. HuH7 adult hepatoma cells (2 × 106) were injected into the left rear and right rear flanks of male NRG mice. Over two weeks, tumors formed: mean volume 130 ± 10 mm3. Animals were treated with vehicle control or with drugs IP daily; aramchol (50 mg/kg), regorafenib (10 mg/kg) or the drugs in combination. Tumor volumes were calculated on the indicated days using the formula (length – longest diameter) × (width)2/2 (n = 20 ± SD) *p < 0.05 less than vehicle control; **p < 0.05 less than aramchol as a single agent. (B) Mouse body mass was determined daily and is presented for those days when tumor volumes were, in parallel, being determined (n = 10 ± SD). There was no significant alteration in mouse body mass over the time course, p > 0.05.
Credit
Copyright: © 2025 Booth et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Usage Restrictions
With credit to the original source.
License
Original content